[Tafamidis for transthyretin amyloid cardiomyopathy]

Larrea N, Bardach A, Argento F, Alfie V, Ciapponi A, Augustovski F, García Martí S, Alcaraz A, Pichon-Riviere A
Record ID 32018004397
Original Title: Tafamidis en cardiomiopatía amiloide por transtirretina
Authors' recommendations: Low-quality evidence shows that adding tafamidis to the standard of care in patients with transthyretin amyloid cardiomyopathy results in a higher net benefit, since it reduces mortality due to all causes in NYHA Functional Class I/II patients when compared to placebo. In addition, it reduces hospitalizations due to cardiovascular causes in this same group. The clinical practice guidelines surveyed recommend using tafamidis in patients with transthyretin amyloid cardiomyopathy. They highlight its benefit in early stages of disease and that patient screening should be adjusted to those subgroups for which there is benefit. No Latin-American health funders covering tafamidis for transthyretin amyloid cardiomyopathy have been found. Most state funders from high-income countries do not include tafamidis in their health coverage plans because of its high cost. France provides coverage with an approximately 60% reimbursement and Canada covers it if price is reduced. Although cost-effective and budget impact studies have not been found in Argentina, its use was not cost-effective in a United States economic evaluation and was specifically excluded from coverage of other health systems in view of its budget impact.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Amyloid Neuropathies, Familial
  • Cardiomyopathies
  • Benzoxazoles
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.